Newly Approved Laser Systems for Onychomycosis

被引：24

作者：

Gupta, Aditya K. ^{[1
,2
]}

Simpson, Fiona ^{[2
]}

机构：

[1] Univ Toronto, Dept Med, Div Dermatol, Toronto, ON, Canada

[2] Mediprobe Res Inc, Toronto, ON, Canada

来源：

JOURNAL OF THE AMERICAN PODIATRIC MEDICAL ASSOCIATION | 2012年 / 102卷 / 05期

关键词：

RECURRENCE;

D O I：

10.7547/1020428

中图分类号：

R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学（修复外科学）];

学科分类号：

摘要：

Laser systems are a new treatment area for onychomycosis. As of January 2012, the US Food and Drug Administration (FDA) has approved four laser systems for the "temporary increase of clear nail in onychomycosis." The FDA has approved these devices on the basis of "substantial equivalence" to predicate devices with similar technical specifications and applications. Laser therapy appears to be a promising alternative to traditional pharmacotherapy, but these systems have been tested in only limited clinical trials; therefore, it is not possible to compare their efficacy to the oral and topical drugs currently used in the treatment of onychomycosis. (J Am Podiatr Med Assoc 102(5): 428-430, 2012)

引用

页码：428 / 430

页数：3

共 11 条

[1] AUSTRALIAN REGISTER OF THERAPEUTIC GOODS, PUBL SUMM 163176
[2] DRUGS@FDA DATABASE, LAM PROD LAB
[3] DRUGS@FDA DATABASE, PENL PROD LAB
[4] DRUGS@FDA DATABASE, SPOR PROD LAB
[5] Gupta AK, 2004, CUTIS, V74, P10
[6] Harrison D., 2009, Practicing chiropractors Committee on Radiology Protocols (PCCRP) for Biomechanical Assessment of spinal subluxation in Chiropractic Clinical Practice, P1
[7] Onychomycosis in clinical practice: factors contributing to recurrence
Scher, RK
Baran, R
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2003, 149 : 5 - 9
[8] US FOOD AND DRUG ADMINISTRATION, 510 K DAT SUMM K0935
[9] US FOOD AND DRUG ADMINISTRATION, 510 K DAT SUMM K1036
[10] US FOOD AND DRUG ADMINISTRATION, 510 K DAT SUMM K1033

← 1 2 →